Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have received an average recommendation of "Buy" from the thirteen brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $88.00.

JANX has been the topic of a number of recent analyst reports. BTIG Research boosted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a report on Friday, December 27th. Stifel Nicolaus boosted their target price on Janux Therapeutics from $70.00 to $115.00 and gave the stock a "buy" rating in a report on Tuesday, December 3rd. Scotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a report on Friday, February 28th. Finally, Leerink Partnrs raised Janux Therapeutics to a "strong-buy" rating in a report on Friday, November 22nd.

Insider Transactions at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The shares were bought at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This trade represents a 1.10 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,002 shares of company stock valued at $2,684,703. 29.40% of the stock is owned by corporate insiders.

Remove Ads

Institutional Trading of Janux Therapeutics

Large investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Janux Therapeutics by 202.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company's stock worth $10,639,000 after purchasing an additional 156,675 shares in the last quarter. Lester Murray Antman dba SimplyRich lifted its position in shares of Janux Therapeutics by 205.3% during the 4th quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company's stock worth $1,301,000 after buying an additional 16,351 shares during the last quarter. Algert Global LLC bought a new stake in shares of Janux Therapeutics during the 3rd quarter worth $1,112,000. Ally Bridge Group NY LLC bought a new stake in shares of Janux Therapeutics during the 3rd quarter worth $4,943,000. Finally, FMR LLC lifted its position in shares of Janux Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 7,824,675 shares of the company's stock worth $355,475,000 after buying an additional 47,075 shares during the last quarter. 75.39% of the stock is owned by institutional investors and hedge funds.

Janux Therapeutics Trading Down 0.4 %

Shares of Janux Therapeutics stock traded down $0.11 on Thursday, reaching $30.64. 653,704 shares of the company were exchanged, compared to its average volume of 818,280. Janux Therapeutics has a one year low of $29.63 and a one year high of $71.71. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -26.19 and a beta of 3.23. The company has a 50-day moving average of $41.27 and a 200 day moving average of $47.48.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.